A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...

Satoru Osuka, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Neurosurgery, has been awarded a $50,000 seed grant from the Uncle Kory Foundation to support ...

Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...

On-demand video webcast now available here HOUSTON, TX / ACCESSWIRE / 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a bi ...

The average life expectancy with GBM is less than 24 months, with a one-year survival rate of 40% and a five-year survival rate of around 5%. There is no clear standard of care for recurrent GBM ...

Russell Bradley Named President & General Manager of CNSideDr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of ...

Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors Dr. Jonathan Stein Appointed CNSide Medical Director AUST ...

Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of ...